Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial - Kim, D-W; Mehra, R; Tan, D SW (Lancet Oncol, 2016)